MARKET

XOMA

XOMA

XOMA Royalty Corporation
NASDAQ
28.92
+0.69
+2.44%
After Hours: 28.92 0 0.00% 16:08 07/25 EDT
OPEN
28.36
PREV CLOSE
28.23
HIGH
30.36
LOW
28.32
VOLUME
100.28K
TURNOVER
0
52 WEEK HIGH
30.36
52 WEEK LOW
13.48
MARKET CAP
336.59M
P/E (TTM)
-7.3777
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XOMA last week (0715-0719)?
Weekly Report · 4d ago
My 2 Top Royalty Income Picks, Yields Up To 9.5%
Seeking Alpha · 07/19 12:30
Weekly Report: what happened at XOMA last week (0708-0712)?
Weekly Report · 07/15 11:29
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
Zevra Therapeutics Inc.’s arimoclomol for Niemann-Pick disease type C (NPC) is expected to be reviewed by the FDA in September. The company acquired arimclomol from Orphazyme for $12.8 million. William Blair reiterates the Outperform rating for Zevra.
Benzinga · 07/09 19:27
Demystifying XOMA: Insights From 5 Analyst Reviews
XOMA Corp is a biotechnology royalty aggregator. The company has an average 12-month price target of $67.2. 5 analysts have released ratings for XOMA in the past three months. The average price target is a decrease from the previous average of $74.00. XomA Corp has a positive revenue growth rate of 240.96% over the past decade.
Benzinga · 07/09 14:01
XOMA CORP - FILED AMENDMENT TO AMENDED CERTIFICATE OF INCORPORATION TO CHANGE NAME OF CO FROM "XOMA CORPORATION" TO "XOMA ROYALTY CORPORATION"
Reuters · 07/09 12:08
Strong Buy Rating for Xoma on Vabysmo’s Market Approval and Financial Prospects
TipRanks · 07/09 10:17
Weekly Report: what happened at XOMA last week (0701-0705)?
Weekly Report · 07/08 11:31
More
About XOMA
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.